Détail d'une collection
Documents disponibles dans la collection
Ajouter le résultat dans votre panier Affiner la recherche
Management of smoking cessation in patients with psychiatric disorders / Karl Fagerström (2009)
Titre : Management of smoking cessation in patients with psychiatric disorders Type de document : texte imprimé Auteurs : Karl Fagerström, Auteur ; Henri-Jean Aubin, Auteur Editeur : Abingdon [Angleterre] : Taylor & Francis Group Année de publication : 2009 Collection : Current medical research and opinion, ISSN 0300-7995 num. 25:2 Importance : p. 511-518 Langues : Anglais (eng) Catégories : [DIVERS] discipline médicale, paramédicale et scientifique:médecine:médecine spécialisée:psychiatrie
[TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] prévention:santé:santé mentale
[TABAC] sevrage tabagique
Index. décimale : TA 6.2 Méthodes individuelles Résumé : BACKGROUND:
There is a close relationship between tobacco smoking and psychiatric disorders, and a higher proportion of individuals with mental health conditions smoke compared with the general population. Due to the increased smoking prevalence in this population, patients with psychiatric conditions are at greater risk of smoking-related morbidity and mortality and experience detrimental effects on their quality of life. However, while the majority of individuals with a history of mental health conditions appreciate that smoking is detrimental to their health, they are less likely to quit smoking and have a lower success rate during quit attempts compared with the general population.
Peer-reviewed articles were identified from PubMed using the inclusive date-range of 1990 - October 2008 and the search terms; depression, mental health, psychiatric disorders, schizophrenia, and smoking cessation. Articles were selected from the search results to provide a general overview of some of the main issues for smokers with psychiatric disorders in general and specifically, those with schizophrenia and depression. The evidence from smoking cessation trials within these populations was also reviewed.
Nicotine has some positive effects on symptoms of psychiatric disorders and it has been proposed that patients with mental health conditions may smoke as a form of self-medication. Further, several studies have shown that some symptoms of psychiatric disorders may be exacerbated by nicotine withdrawal. Therefore, attempts to quit smoking pose additional problems to patients with mental health problems.
Traditional programmes for smoking cessation may not always be suitable for psychiatric patients due to their neuropsychological profile. Preliminary evidence suggests that more flexible, open-ended, combination approaches of pharmacotherapy and counselling may be more successful. In addition, identification and treatment of nicotine addiction remains very low in patients with mental health conditions and far more needs to be done to raise the awareness and ability of psychiatrists to diagnose and treat patients with nicotine problems.
En ligne : https://pubmed.ncbi.nlm.nih.gov/19192999/ Permalink :
Code-barres Cote Support Localisation Section Disponibilité TA 005644 TA 6.2 FAG M Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêt
Aucun avis, veuillez vous identifier pour ajouter le vôtre !The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers / Raymond S. Niaura (2008)
Titre : The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers : a randomized controlled trial Type de document : texte imprimé Auteurs : Raymond S. Niaura, Auteur ; J. Taylor Hays, Auteur ; Douglas E. Jorenby, Auteur Editeur : Abingdon [Angleterre] : Taylor & Francis Group Année de publication : 2008 Collection : Current medical research and opinion, ISSN 0300-7995 num. Vol 24, n. 7 Importance : p. 1931-1941 Présentation : graph., tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
Index. décimale : TA 220.127.116.11.4 Autres substituts nicotiniques Résumé : Abstract
To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation.
RESEARCH DESIGN AND METHODS:
320 healthy, motivated-to-quit smokers (> or =10 cigarettes/day) aged 18-65 years, entered a multicenter, randomized, double-blind, placebo-controlled study - conducted between December 26, 2001 and June 24, 2003 - with a 12-week treatment phase and 40-week, double-blind, non-treatment follow-up. Treatment consisted of varenicline or placebo in fixed doses (Week 1: titrated from 0.5 to 1.0 mg/day) followed by a self-regulated flexible schedule (Weeks 2-12: 0.5-2.0 mg/day).
MAIN OUTCOME MEASURES:
Primary outcomes included carbon monoxide-confirmed continuous abstinence rate (CAR) from smoking for Weeks 4 through 7, 9 through 12, and 9 through 52. Secondary outcomes included CAR from Weeks 9 through 24, 7-day point prevalence of abstinence, safety assessments, and measures of craving, withdrawal, and smoking reward.
Superior CARs were observed in varenicline-treated (n = 157) versus placebo participants (n=155) for Weeks 4 through 7 (38.2 vs. 11.6%), 9 through 12 (40.1 vs. 11.6%), 9 through 24 (28.0 vs. 9.0%), and 9 through 52 (22.3 vs. 7.7%) (all p CONCLUSIONS:
A self-regulated, flexible dosing regimen of varenicline is well tolerated, with superior effectiveness versus placebo for smoking cessation.
Code-barres Cote Support Localisation Section Disponibilité TA 005481 TA 18.104.22.168.4 NIA E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêt
Aucun avis, veuillez vous identifier pour ajouter le vôtre !